

DUX4, the rockstar of embryonic genome activation?

SONJA NYKÄNEN, SANNA VUORISTO*

Stem Cells and Metabolism Research Program; Helsinki Institute of Life Science;
and Department of Obstetrics and Gynecology, University of Helsinki, Finland

ABSTRACT During the initial days of development, the embryo gradually shifts from reliance on maternally provided RNAs and proteins to regulation of its own development. This transition is marked by embryonic genome activation (EGA). While the factors driving human EGA remain poorly characterized, accumulating evidence suggests that double homeobox 4 (DUX4) is an important regulator of this process. Despite advances in single-cell methods which have allowed studies in early human embryos, fundamental questions regarding the function and regulation of DUX4 persist. Here, we review current knowledge of DUX4 with a focus on EGA in humans.

KEYWORDS: Double Homeobox 4 (DUX4), embryo development, embryonic genome activation, gene regulation, non-coding genome

Introduction

The oocyte-to-embryo transition culminates in the degradation of maternal transcripts and in embryonic genome activation (EGA) (Schulz and Harrison, 2019; Vastenhouw *et al.*, 2019). The transcriptome changes prominently during the oocyte-to-four cell and four-to-eight cell transitions that are considered as the minor and major EGA stages, respectively (Braude, 1988; Petropoulos *et al.*, 2016; Tesařík, 1988; Töhönen *et al.*, 2015; Vassena *et al.*, 2011; Xue *et al.*, 2013; Yan *et al.*, 2013). In addition to the activation of key developmental genes, the non-coding genome that contributes to genome regulation becomes extensively transcribed (Bouckenheimer *et al.*, 2016; Paloviita and Vuoristo, 2022). The activation of the embryonic transcriptome is intricately linked with major alterations in the epigenome and chromatin architecture (Chen *et al.*, 2019; Liu *et al.*, 2019; Wu *et al.*, 2018; Xia *et al.*, 2019). It is conceivable that EGA takes place only in a favorable epigenomic landscape that generates adequate conditions for timely gene regulation. How these processes are regulated in human fertilized oocytes and pre-implantation embryos, and whether the factors involved exhibit redundancy, remain poorly understood.

DUX4 belongs to a group of double homeobox genes that are unique to placental mammals. These genes are characterized by two proximal homeoboxes that encode DNA-binding homeodomains (Gabriëls *et al.*, 1999). The primate specific DUX4 is believed to have originated through retro-transposition of the ancestral DUXC gene, followed by the loss of DUXC from the primate genome (Leidenroth *et al.*, 2012). DUX4 mRNA is enriched in human zygotes and cleavage-stage embryos (De Iaco *et al.*, 2017; Hendrickson *et al.*, 2017; Liu *et al.*, 2019; Töhönen *et al.*, 2017; Vuoristo *et al.*,

2022). Silencing of DUX4 in human embryos leads to inefficient degradation of maternal transcripts and incomplete EGA, which implies a potential role of DUX4 as an EGA regulator (Liu *et al.*, 2022; Vuoristo *et al.*, 2022). Human embryonic stem cells (hESCs) have been used to elucidate possible roles of selected EGA factors given the shortage of supernumerary embryos donated for research and the fact that experiments in human embryos are challenging due to ethical and technical limitations (Gawriyski *et al.*, 2023; Hendrickson *et al.*, 2017; Madisson *et al.*, 2016; Vuoristo *et al.*, 2022; Zou *et al.*, 2022). In hESCs, ectopic expression of DUX4 activates both coding and non-coding genes that are typically active in early human embryo at the time of EGA (Hendrickson *et al.*, 2017; Taubenschmid-Stowers *et al.*, 2022; Vuoristo *et al.*, 2022; Yoshihara *et al.*, 2022). These findings collectively suggest a pivotal role for DUX4 in regulating human EGA. In this review, we aim to provide the latest insight into DUX4 and discuss its significance in the context of human EGA.

The peculiar DUX4 repeat locus

The DUX4 open reading frames are located in the subtelomeric region of chromosome 4, within a macrosatellite repeat region known as D4Z4 (Gabriëls *et al.*, 1999) (Fig. 1). While the D4Z4 repeat array is typically epigenetically repressed in most tissues, it becomes transiently derepressed in human embryos possibly due to global epigenome reprogramming (De Iaco *et al.*, 2017;

Abbreviations used in this paper: DUX4, Double Homeobox 4; EGA, Embryonic genome activation; FSHD, Facioscapulohumeral muscular dystrophy; TE, Transposable element.

*Address correspondence to: Sanna Vuoristo. Stem Cells and Metabolism Research Program, University of Helsinki, 00014 Helsinki, Finland.
E-mail: sanna.vuoristo@helsinki.fi | https://orcid.org/0000-0003-4735-3914

Hendrickson *et al.*, 2017; Liu *et al.*, 2019; Vuoristo *et al.*, 2022; Xia *et al.*, 2019). The repetitive nature, high GC content, and low expression level of *DUX4* pose challenges for sequencing and annotation of this genomic region, particularly when working with human embryos that are available in limited numbers. Most of our current knowledge about *DUX4* stems from research on its involvement in the pathogenesis of facioscapulohumeral muscular dystrophy (FSHD) (Campbell *et al.*, 2018). FSHD is caused by derepression of *D4Z4* locus which likely leads to a burst of *DUX4* expression in a subset of affected muscle cells resulting in cell death (Rickard *et al.*, 2015; Snider *et al.*, 2010). The derepression of *D4Z4* locus is caused by either a reduction of *D4Z4* repeat units alone (FSHD1), or defects in *D4Z4* chromatin repressor SMCHD1 (FSHD2), or both (FSHD1+2) (Hewitt, 2015; Sacconi *et al.*, 2019). Interestingly, a nearly identical *D4Z4* repeat array exists on chromosome 10, but the contraction of this repeat array does not cause FSHD presumably due to the lack of a permissive polyadenylation signal (Lemmers *et al.*, 2010). The toxic effect of *DUX4* in FSHD pathophysiology is not yet completely understood but the mechanisms likely involve the activation of the MYC-mediated apoptotic pathway and the double-stranded RNA innate immune response pathway (Shadle *et al.*, 2017), as well as repression of nonsense-mediated decay (NMD) (Campbell *et al.*, 2023; Feng *et al.*, 2015; Jagannathan *et al.*, 2019). Notably, *DUX4* is cytotoxic not only for muscle cells but also for various other cell types (Kowaljow *et al.*, 2007; Resnick *et al.*, 2019; Rickard *et al.*, 2015; Wallace *et al.*, 2011; Yoshihara *et al.*, 2022). Given that in human embryos MYC expression is only upregulated at the time of major EGA stage, the first two days of development take place without one of the main factors behind *DUX4*-induced cell death. This could be one of the reasons why human embryos tolerate short-term *DUX4* expression.

Although each repeat unit in the *D4Z4* array contains the *DUX4* open reading frame, the current conception is that functional *DUX4* transcripts originate from the last repeat unit (Fig. 1). This is explained by the position of the polyadenylation signal, which is

distal to the repeat array and thus transcribed exclusively as part of the last repeat (Dixit *et al.*, 2007). Consequently, individuals that have a contracted *D4Z4* repeat region but lack the distal polyadenylation signal exhibit a normal muscle phenotype (Lemmers *et al.*, 2010). In addition to the *DUX4* mRNA isoforms that are transcribed from the *D4Z4* array on chromosome 4 and use the conventional polyadenylation signal, numerous isoforms that utilize alternative polyadenylation sites have been described to originate from both chromosome 4 and 10. These isoforms likely result from alternative splicing, however the mechanisms that control the splicing of *DUX4* transcripts remain obscure. Moreover, it is unclear which mRNA isoforms give rise to functional *DUX4* proteins. Testis and some cancer cell lines express *DUX4* transcripts that most likely produce a complete *DUX4*, as indicated by immunofluorescence stainings and the activation of *DUX4* target genes (Smith *et al.*, 2023; Snider *et al.*, 2010). In contrast, various somatic tissues, including healthy muscle, express low levels of capped and polyadenylated *DUX4* transcript isoform, which probably produces a truncated protein that lacks the transcription activation domain and, consequently, the ability to activate *DUX4* targets (Snider *et al.*, 2010). *DUX4* mRNA isoforms present in human embryos have not been described.

The properties of *DUX4*

The *DUX4* protein contains an N-terminal DNA binding domain and C-terminal transcription activation domains (Lee *et al.*, 2021; Mitsuhashi *et al.*, 2018; Vuoristo *et al.*, 2022). The N-terminal DNA-binding domain of *DUX4* includes two homeodomains, HD1 and HD2, that arose from an internal duplication of a single homeodomain and consequently, exhibit a high degree of similarity (Leidenroth and Hewitt, 2010). A primate specific mutation changing arginine to glutamate in HD1 have led to the different target DNA sequence preferences of HD1 and HD2; 5'-TAAT-3' and 5'-TGAT-3', respectively (Lee *et al.*, 2018). *DUX4* has been shown to regulate a




Fig. 1. The *D4Z4* repeat array and *DUX4* mRNA isoforms. The protein coding *DUX4* transcripts are thought to originate from the last *D4Z4* repeat unit and to utilize exons distal to the repeat array that provide canonical polyadenylation signals (PAS). *DUX4* transcript isoforms are generated through alternative splicing, but the regulation of this process is poorly understood. In facioscapulohumeral muscular dystrophy (FSHD) muscle, *DUX4* mRNA contains exons 1-2-3, and the first intron is alternatively spliced (Snider *et al.*, 2010). Testicular tissue expresses *DUX4* mRNA isoforms with exons 1-2-4-5-6-7 and 1-2-6-7 (Snider *et al.*, 2010). Healthy myoblasts use a cryptic splice site within the first exon and

express a *DUX4* mRNA isoform that is predicted to give rise to a truncated *DUX4* (short *DUX4* or *DUX4*-s) that contains the N-terminal homeodomains, but lacks the C-terminus (Snider *et al.*, 2010). Additional *DUX4* mRNA isoforms that utilize alternative polyadenylation signals are likely to exist (Smith *et al.*, 2023). The asterisk (*) indicates the location of the translation stop codon. Abbreviations: C-term, C-terminus; *DUX4*, double homeobox 4; HD, homeodomain; PAS, polyadenylation signal.

set of transposable elements (TEs) (Vuoristo *et al.*, 2022; Young *et al.*, 2013). Hence, the unique HD1 target sequence in primates, as opposed to other mammals, may have evolved as a consequence of co-evolution with species-specific TEs (Lee *et al.*, 2018).

While all the human DUX family members, including DUX4, DUXA and DUXB, contain the N-terminal DNA-binding domain, only DUX4 possesses the conserved C-terminal domain (Leidenroth and Hewitt, 2010). The C-terminus of DUX4 contains a nine amino acid transactivation domain (9aaTAD) (Mitsuhashi *et al.*, 2018) and a KIX-binding motif (KBM) (Vuoristo *et al.*, 2022). The C-terminal domain is essential for DUX4-mediated transcriptional activation and cytotoxicity (Bosnakovski *et al.*, 2008; Choi *et al.*, 2016; Mitsuhashi *et al.*, 2018). Consequently, DUXA and DUXB, which lack the C-terminal domain, are incapable of activating transcription and do not cause cytotoxicity (Bosnakovski *et al.*, 2023). The region between the N-terminal homeodomains and C-terminal transactivating domain is predicted to be intrinsically disordered (Mitsuhashi *et al.*, 2018). While many transcription factors contain an intrinsically disordered region (IDR), the precise nature of their function is not well understood (Ferrie *et al.*, 2022). The deletion of the region between homeodomains and C-terminus does not affect the activation of the known DUX4 target gene *ZSCAN4* (Choi *et al.*, 2016; Mitsuhashi *et al.*, 2018) nor does it protect from the DUX4-elicited cell death in myoblasts (Choi *et al.*, 2016) and HEK293 cells (Mitsuhashi *et al.*, 2018). However, further studies are required to determine whether the IDR lacking form of DUX4 can fully recapitulate the function of full-length DUX4.

DUX4 in EGA regulation

DUX4 was first associated with embryogenesis when it was observed to activate early developmental genes in muscle cells of FSHD patients (Geng *et al.*, 2012). Since then, experiments conducted in various cell types, including human myoblasts (Jagannathan *et al.*, 2016; Resnick *et al.*, 2019; Rickard *et al.*, 2015), human pluripotent stem cells (De Iaco *et al.*, 2017; Hendrickson *et al.*, 2017; Taubenschmid-Stowers *et al.*, 2022; Vuoristo *et al.*, 2022; Whiddon *et al.*, 2017; Yoshihara *et al.*, 2022), and most recently various cancer cell lines (Smith *et al.*, 2023), have consistently reported the activation of genes and TEs characteristic of early embryos upon induced or spontaneous *DUX4* expression. *DUX4* mRNA is enriched in zygotes and early cleavage stage embryos (De Iaco *et al.*, 2017; Liu *et al.*, 2019; Töhönen *et al.*, 2017; Vuoristo *et al.*, 2022). *DUX4* protein shows nuclear accumulation in 2- and 4- cell stage embryos followed by rapid clearance by the 8-cell stage (Hendrickson *et al.*, 2017; Vuoristo *et al.*, 2022). Given the ethical and technical challenges associated with research involving human embryos, many insights into the *DUX4* functions have been derived from the studies conducted using inducible *DUX4* transgene cell lines. Inspired by these findings, the scientific community has recognized *DUX4* as one of the earliest regulators of EGA.

DUX4 activates the non-coding genome

In accordance with the timing of the nuclear localization of *DUX4* (Vuoristo *et al.*, 2022), the accessible genomic regions in 2-cell and 4-cell embryos are enriched with *DUX4* binding motifs (Hendrickson *et al.*, 2017; Liu *et al.*, 2019; Wu *et al.*, 2018). Accessible chromatin regions in human cleavage stage embryos are frequently located at distal sites (> 5 kb from the transcriptional

start sites) of genes and enriched at TEs (Gao *et al.*, 2018; Liu *et al.*, 2019; Wu *et al.*, 2018). TEs are mobile genetic elements constituting approximately half of the human genome (Franke *et al.*, 2017). TEs are enormously diverse and divided into distinct classes and families based on their modes of transposition, structural features, and evolutionary relationship (Bourque *et al.*, 2018). TEs promote genetic diversity by moving within the genome, which can lead to alterations in host genes and regulatory sequences. This mobility poses a significant risk to genome stability, and therefore several mechanisms have evolved to suppress TEs (Almeida *et al.*, 2022).

Human TEs are transcriptionally and post-transcriptionally repressed by various chromatin remodellers, Krüppel-associated box (KRAB) domain-containing zinc finger proteins, and small RNAs (Almeida *et al.*, 2022; Gainetdinov *et al.*, 2017; Janssen *et al.*, 2018). However, a substantial proportion of TEs, including human endogenous retroviral (HERV) elements, are transiently active during pre-implantation development (DiRusso and Clark, 2023; Göke *et al.*, 2015; Grow *et al.*, 2015; Liu *et al.*, 2019; Pontis *et al.*, 2019; Xu *et al.*, 2022). For instance, *MLT2A1* elements that are members of the HERV family, become accessible and transcribed at the 4-cell stage, retain these states for the 8-cell stage, but are subsequently repressed (Liu *et al.*, 2019). Notably, *DUX4* overexpression in hESCs leads to the binding of *DUX4* to 30% of the embryonically accessible *MLT2A1* elements (Hendrickson *et al.*, 2017; Liu *et al.*, 2019). *DUX4* also activates transcription of various other TEs (Geng *et al.*, 2012; Hendrickson *et al.*, 2017; Vuoristo *et al.*, 2022; Young *et al.*, 2013), and for example, the EGA genes *ZSCAN4* and *KHDC1P1* are regulated by *DUX4*-activated ERVL-MaLR overlapping enhancers in *DUX4*-expressing hESCs (Vuoristo *et al.*, 2022). Some TEs have been evolutionarily co-opted to regulate species- and context-specific gene expression programs (Franke *et al.*, 2017; Hashimoto *et al.*, 2021; Liang *et al.*, 2010; Macaulay *et al.*, 2011; Pontis *et al.*, 2019; Whiddon *et al.*, 2017), and we speculate that some *DUX4*-induced TEs may have been co-opted to regulate human EGA transcripts.

Mechanisms of DUX4-mediated gene regulation

DUX4 has the capacity to modulate nucleosome structure by inducing the expression and incorporation of histone variants H3.X and H3.Y, which are associated with a relaxed chromatin state and enhanced transcription of the *DUX4* target genes (Resnick *et al.*, 2019). In myoblasts, induced *DUX4* expression leads to the incorporation of H3.X/Y into highly transcribed *DUX4* target genes, potentially contributing to the maintenance of an open chromatin conformation (Resnick *et al.*, 2019). Studies on protein-protein interactions in myoblasts and HEK293 cells have shown that *DUX4* can interact with histone acetyltransferases p300 and the CREB binding protein (CBP) (Choi *et al.*, 2016; Vuoristo *et al.*, 2022). These histone acetyltransferases are typically recruited to enhancers by transcription factors, resulting in local acetylation of H3K27 and subsequent expression of target genes (Raisner *et al.*, 2018). *DUX4* interacts with p300/CBP through its C-terminus, and the deletion of the last 98 amino acids of the *DUX4* C-terminus disrupts the interaction with both p300 and CBP (Choi *et al.*, 2016). The expression of several *DUX4* target genes is reduced when the interaction of p300/CBP with *DUX4* is disrupted by the *DUX4* C-terminal deletion (Choi *et al.*, 2016) or by p300/CBP inhibition (Bosnakovski *et al.*, 2019), suggesting that transcriptional activation of certain *DUX4* target genes depends on p300/CBP. Furthermore, *DUX4* can interact with several chromatin modifiers and transcriptional




Fig. 2. A summary of the suggested mechanisms of action of DUX4. DUX4 accumulates in the nuclei of two- and four-cell stage human embryos and is subsequently cleared by the 8-cell stage (left) (Hendrickson *et al.*, 2017; Vuoristo *et al.*, 2022). DUX4 regulates chromatin accessibility (Resnick *et al.*, 2019; Vuoristo *et al.*, 2022), and interacts with various proteins, such as histone acetyltransferase p300 (Choi *et al.*, 2016) and mediator complex members (Vuoristo *et al.*, 2022), which are involved in transcriptional regulation. DUX4 activates several embryonic genome activation (EGA)-associated genes, repetitive elements (De Iaco *et al.*, 2017; Geng *et al.*, 2012; Hendrickson *et al.*, 2017; Liu *et al.*, 2019; Vuoristo *et al.*, 2022) and putative enhancers (Vuoristo *et al.*, 2022), and it was recently implicated in inhibition of translation initiation and elongation (Hamm *et al.*, 2023). Abbreviations: DUX4, double homeobox 4; eRNA, enhancer RNA; H3K27ac, histone 3 lysine 27 acetylation; MED, mediator complex; mRNA, messenger RNA.

modifiers both stably and transiently (Vuoristo *et al.*, 2022). DUX4 interacts with several mediator complex family members that relay regulatory signals from transcription factors to RNA polymerase II (Chen *et al.*, 2021). DUX4 binds MED15 via the six amino acid KIX binding motif, which is located at the very end of the DUX4 C-terminus (Vuoristo *et al.*, 2022). This interaction presents another direct mechanism of DUX4-mediated transcriptional modulation. Besides transcriptional regulation, DUX4 has been implicated in translational regulation. A recent study showed that induced *DUX4* expression leads to translational suppression of numerous mRNAs in myoblasts (Hamm *et al.*, 2023). The DUX4-mediated regulation of translation is likely attributed to alterations in the activity of translation initiation regulators 4EBP1, eIF4E, and elongation factor eEF2, however, the intermediate mechanisms responsible for perturbing these factors remain unknown (Hamm *et al.*, 2023). Taken together, DUX4 emerges as a versatile regulator, engaging with a variety of proteins to shape transcription and translation processes (summarized in Fig. 2). Further research is needed to elaborate implications of the DUX4 protein interactions and unravel the precise regulatory mechanisms downstream of DUX4.

Regulation of DUX4 expression

DUX4 transcripts have not been detected in oocytes, indicating that *DUX4* is embryonically expressed, however factors and processes responsible for triggering *DUX4* expression in human embryos remain unknown. In a study by Grow *et al.*, an LTR element (LTR10C) near the *DUX4* gene was identified as a *DUX4* enhancer in myoblasts and induced pluripotent stem cells (iPSC) that were derived from FSHD patients (Grow *et al.*, 2021). This enhancer was found to be bound by p53, a transcription factor that is activated in response to DNA damage, and as shown by CRISPR interference is required for full p53-dependent activation of the *DUX4* locus in

FSHD iPSC (Grow *et al.*, 2021). However, p53 binding alone is insufficient to cause activation of *DUX4* expression as the enhancer also becomes occupied by p53 in non-FSHD cells upon induction of DNA damage. Therefore, it is likely that p53-induced *DUX4* expression entails additional prerequisites such as inefficient epigenetic repression, as is observed in FSHD (Grow *et al.*, 2021). Notably, telomere shortening, a phenomenon observed both in FSHD (Stadler *et al.*, 2013) and human embryos up to the 4-cell stage, may result in the loss of H3K9 methylated heterochromatin at the *DUX4* locus (Zhang *et al.*, 2023). This decrease in epigenetic repression is suggested to facilitate p53 binding to the LTR10C enhancer subsequently leading to the activation of *DUX4* (Zhang *et al.*, 2023).

EGA is required for zygotic development, but it is equally important that this unique transcription program is timely repressed as development progresses. The level of H3K9me3, which is strongly associated with densely packed and transcriptionally silenced heterochromatin, gradually accumulates during human pre-implantation development (van de Werken *et al.*, 2014; Xia *et al.*, 2019; Xu *et al.*, 2022; Yu *et al.*, 2022). While some TEs are marked by H3K9me3 throughout development, others gain H3K9me3 in a stage-specific manner (Xu *et al.*, 2022; Yu *et al.*, 2022), strongly implying their developmental stage-specific involvement in cis-regulatory functions during human embryogenesis. Mechanisms behind the selective temporal repression of specific genomic loci during human EGA remains poorly understood. Mouse DUX, a homolog of DUX4, has been suggested to contribute to the establishment of H3K9me3 by inducing the expression of DUXBL, which is subsequently recruited to DUX-bound regions with the TRIM24/33 complex to facilitate the silencing of the associated genes and TEs (Vega-Sendino *et al.*, 2024). A recent study proposes an analogous mechanism in humans, where DUXA that is expressed in the 8-cell

stage embryos (Töhönen *et al.*, 2015), potentially contributes to the repression of DUX4 target loci (Bosnakovski *et al.*, 2023). DUXA DNA binding motifs are highly similar to those of DUX4 (Liu *et al.*, 2019), however DUXA lacks the C-terminal transactivating domain, presumably abolishing its ability to activate transcription (Bosnakovski *et al.*, 2023). Remarkably, when both DUX4 and DUXA are ectopically expressed in myoblasts, the expression levels of DUX4 target genes are significantly reduced (Bosnakovski *et al.*, 2023). DUXA expression is activated by DUX4, which points to a feedback inhibition mechanism where DUXA suppresses DUX4 targets, possibly as a result of competitive target sequence binding by DUX4 and DUXA (Bosnakovski *et al.*, 2023).

The mechanisms of DUX4 repression in human embryos and somatic tissues remain unclear, however it is conceivable that multiple epigenetic mechanisms, such as DNA methylation and H3K9me3 mediated heterochromatin formation, contribute to this. In mouse 2-cell embryos, the relocation of *Dux* loci to the nucleolar periphery potentially drives the repression of *Dux* through the formation of perinucleolar heterochromatin, concurrently with the maturation of nucleoli (Xie *et al.*, 2022; Yu *et al.*, 2021). Also in human embryos, nucleoli maturation initiates around the time of EGA (Tesarik *et al.*, 1986) and coincides with the repression of DUX4 (Kresoja-Rakic and Santoro, 2019). However, whether nucleolar maturation contributes to DUX4 repression in humans remains a topic for future research. Due to the location of DUX4 in the subtelomeric region, it may be affected by the transcriptional repression induced by the spread of telomeric heterochromatin, named telomere position effect (TPE) (Lee *et al.*, 2021). Zhang *et al.*, have provided evidence that telomere extension may contribute to the silencing of DUX4 in human embryos, supported by the observation that telomere length extends during major ZGA (Zhang *et al.*, 2023) and longer telomeres lead to pronounced TPE (Baur *et al.*, 2001).

Future prospects

Ever since DUX4 was recognized as a potent EGA factor it has raised broad interest across the research community. Earlier findings about DUX4 that were mainly focused on the etiology of FSHD, have become augmented by recent perceptions that DUX4 actively modulates embryonic gene expression and embryonic development. Yet several important questions about DUX4 and its implications in human oocyte-to-embryo transition and EGA remain unanswered. Current DUX4 annotations rely on the DUX4 sequences found in human somatic cells like myoblasts and therefore, it is possible that human zygotes express DUX4 sequence variants. Cloning and sequencing of the full-length DUX4 mRNA from zygotes and cleavage stage embryos using traditional PCR-based technologies may be complicated due to the repetitive nature and high GC content of this transcript (Jagannathan *et al.*, 2016). Therefore, recent technological improvements in long read sequencing may prove to be useful in determining the DUX4 mRNA sequence in human embryonic samples. Relatedly, recent findings according to which the canonical DUX4 interacts with numerous chromatin modifiers, RNA-binding proteins, and transcriptional modifiers open an interesting avenue to study which of these interactions take place in a context-dependent manner and how these interactions may pertain to embryonic development.

Our understanding about the implications of DUX4 in human

development is restricted, mainly due to ethical and technical limitations related to experiments where human embryos are used. Downscaling the amount of input material needed to perform for instance chromatin profiling has enabled informative analyses about oocytes and preimplantation human embryos. As an example, LiCAT-sequencing that requires low input material (Liu *et al.*, 2019) allowed Zhang *et al.*, to correlate chromatin accessibility at the DUX4 regulatory region with DUX4 expression levels and telomere length during EGA (Zhang *et al.*, 2023). These types of approaches clarify the possible mechanisms behind the onset of DUX4 expression in human development. While mutating of the DUX4 transcription start site in human zygotes leads to embryo stalling by the 8-cell stage (Liu *et al.*, 2022), the knockdown of DUX4 leads to impaired oocyte-to-embryo transition (Vuoristo *et al.*, 2022). This indicates that RNAi-mediated knockdown of DUX4 at zygotic stage may not reveal a complete DUX4 phenotype. The EGA-associated coding transcripts are relatively well-known, however another interesting research avenue will be to investigate the implications of TEs that are activated at the time of EGA. Transcriptome and translome profiling of preimplantation human embryos in combination with extensive functional experiments emphasized the importance of both maternal and zygotic transcription factors (Zou *et al.*, 2022). These factors include TPRXL and OTX2 that are of maternal origin and undergo translation starting from the oocyte meiotic resumption (Zou *et al.*, 2022). The OTX2 is highly expressed in human oocytes (Xue *et al.*, 2013; Yan *et al.*, 2013), and its binding motif is enriched at accessible chromatin regions in the early embryo (Liu *et al.*, 2019), indicating that it functions temporally in parallel with DUX4. Simultaneous knockdown of TPRXL and embryonically expressed TPRX1 and TPRX2 results in developmental delay and impaired EGA, while knockdown of these factors individually caused milder phenotypes (Zou *et al.*, 2022). EGA-associated factors presumably form a transcriptional circuitry in their specific epigenome landscape. Further research is imperative to understand how these factors function and to what extent each of these factors may be indispensable for development or whether they can compensate for one another. One of the challenges related to research on human EGA factors is their highly unique *in vivo* state, which is difficult to recapitulate *in vitro*. Recently acknowledged 8-cell embryo-like cellular model systems provide promising platforms for future studies (Mazid *et al.*, 2022; Moya-Jódar *et al.*, 2023; Taubenschmid-Stowers *et al.*, 2022; Yoshihara *et al.*, 2022; Yu *et al.*, 2022), although they lack some of the key *in vivo* aspects such as the presence of maternal factors. As a summary, recent studies have emphasized the role of DUX4 as one of the active transcription factors during human EGA and focused on discovering how DUX4 may become activated, and how it regulates its target sequences. Future research is imperative to further elucidate mechanisms of DUX4 and other EGA factors in the context of human EGA and in cellular reprogramming.

Acknowledgments

We acknowledge MSc. Pauliina Paloviita, Dr. Michelle Percharde and Dr. Edward Grow for critical reading of the manuscript and helpful comments. This work was supported by the University of Helsinki Doctoral Programme in Biomedicine (S.N.), the Finnish Fertility Society (S.N.), the University of Helsinki Three-year grant (S.V.), the Sigrid Jusélius Senior Researcher grant (S.V.), the Helsinki Institute of Life Science Fellowship (S.V.), and the Academy of Finland Academy fellowship grant #348111 and #353549 (S.V.).

References

- ALMEIDA M. V., VERNAZ G., PUTMAN A. L. K., MISKA E. A. (2022). Taming transposable elements in vertebrates: from epigenetic silencing to domestication. *Trends in Genetics* 38: 529-553. <https://doi.org/10.1016/j.tig.2022.02.009>
- BAUR J. A., ZOU Y., SHAY J. W., WRIGHT W. E. (2001). Telomere Position Effect in Human Cells. *Science* 292: 2075-2077. <https://doi.org/10.1126/science.1062329>
- BOSNAKOVSKI D., DA SILVA M. T., SUNNYS T., ENER E. T., TOSO E. A., YUAN C., CUI Z., WALTERS M. A., JADHAV A., KYBA M. (2019). A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death. *Science Advances* 5: eaaw7781. <https://doi.org/10.1126/sciadv.aaw7781>
- BOSNAKOVSKI D., LAMB S., SIMSEK T., XU Z., BELAYEW A., PERLINGEIRO R., KYBA M. (2008). DUX4c, an FSHD candidate gene, interferes with myogenic regulators and abolishes myoblast differentiation. *Experimental Neurology* 214: 87-96. <https://doi.org/10.1016/j.expneurol.2008.07.022>
- BOSNAKOVSKI D., TOSO E. A., ENER E. T., GEARHART M. D., YIN L., LÜTTMANN F. F., MAGLI A., SHI K., KIM J., AIHARA H., KYBA M. (2023). Antagonism among DUX family members evolved from an ancestral toxic single homeodomain protein. *iScience* 26: 107823. <https://doi.org/10.1016/j.isci.2023.107823>
- BOUCKENHEIMER J., ASSOUS S., RIQUIER S., HOU C., PHILIPPE N., SANSAC C., LAVABRE-BERTRAND T., COMMEST, LEMAÎTRE J. M., BOUREUX A., DEVOS J. (2016). Long non-coding RNAs in human early embryonic development and their potential in ART. *Human Reproduction Update* 23: 19-40. <https://doi.org/10.1093/humupd/dmw035>
- BOURQUE G., BURNS K. H., GEHRING M., GORBUNOVA V., SELUANOV A., HAMMELL M., IMBEAULT M., IZSVÁK Z., LEVIN H. L., MACFARLAN T. S., MAGER D. L., FESCHOTTE C. (2018). Ten things you should know about transposable elements. *Genome Biology* 19: 199. <https://doi.org/10.1186/s13059-018-1577-z>
- BRAUDE P., BOLTON V., MOORE S. (1988). Human gene expression first occurs between the four- and eight-cell stages of preimplantation development. *Nature* 332: 459-461. <https://doi.org/10.1038/332459a0>
- CAMPBELL A. E., BELLEVILLE A. E., RESNICK R., SHADLE S. C., TAPSCOTT S. J. (2018). Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle. *Human Molecular Genetics* 27: R153-R162. <https://doi.org/10.1093/hmg/ddy162>
- CAMPBELL A. E., DYLE M. C., ALBANESE R., MATHENY T., SUDHEENDRAN K., CORTÁZAR M. A., FORMAN T., FU R., GILLEN A. E., CARUTHERS M. H., FLOORS N., CALVIELLO L., JAGANNATHAN S. (2023). Compromised nonsense-mediated RNA decay results in truncated RNA-binding protein production upon DUX4 expression. *Cell Reports* 42: 112642. <https://doi.org/10.1016/j.celrep.2023.112642>
- CHEN X., KE Y., WU K., ZHAO H., SUN Y., GAO L., LIU Z., ZHANG J., TAO W., HOU Z., LIU H., LIU J., CHEN Z. J. (2019). Key role for CTCF in establishing chromatin structure in human embryos. *Nature* 576: 306-310. <https://doi.org/10.1038/s41586-019-1812-0>
- CHEN X., YIN X., LI J., WU Z., QI Y., WANG X., LIU W., XU Y. (2021). Structures of the human Mediator and Mediator-bound preinitiation complex. *Science* 372: 6546. <https://doi.org/10.1126/science.abg0635>
- CHOI S. H., GEARHART M. D., CUI Z., BOSNAKOVSKI D., KIM M., SCHENNUM N., KYBA M. (2016). DUX4 recruits p300/CBP through its C-terminus and induces global H3K27 acetylation changes. *Nucleic Acids Research* 44: 5161-5173. <https://doi.org/10.1093/nar/gkw141>
- DEIACO A., PLANETE E., COLUCCIO A., VERP S., DUC J., TRON O. D. (2017). DUX-family transcription factors regulate zygotic genome activation in placental mammals. *Nature Genetics* 49: 941-945. <https://doi.org/10.1038/ng.3858>
- DIRUSSO J. A., CLARK A. T. (2023). Transposable elements in early human embryo development and embryo models. *Current Opinion in Genetics & Development* 81: 102086. <https://doi.org/10.1016/j.gde.2023.102086>
- DIXIT M., ANSSEAU E., TASSIN A., WINOKUR S., SHI R., QIAN H., SAUVAGE S., MATTÉOTTI C., VAN ACKER A. M., LEO O., FIGLEWICZ D., BARRO M. *et al.* (2007). DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. *Proceedings of the National Academy of Sciences* 104: 18157-18162. <https://doi.org/10.1073/pnas.0708659104>
- FENG Q., SNIDER L., JAGANNATHAN S., TAWIL R., VAN DER MAAREL S. M., TAPSCOTT S. J., BRADLEY R. K. (2015). A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy. *eLife* 4: e04996. <https://doi.org/10.7554/eLife.04996>
- FERRIE J. J., KARR J. P., TJIAN R., DARZACQ X. (2022). "Structure"-function relationships in eukaryotic transcription factors: The role of intrinsically disordered regions in gene regulation. *Molecular Cell* 82: 3970-3984. <https://doi.org/10.1016/j.molcel.2022.09.021>
- FRANKE V., GANESH S., KARLIC R., MALIK R., PASULKA J., HORVAT F., KUZMAN M., FULKA H., CERNOHORSKA M., URBANOVA J., SVOBODOVA E., MA J. *et al.* (2017). Long terminal repeats power evolution of genes and gene expression programs in mammalian oocytes and zygotes. *Genome Research* 27: 1384-1394. <https://doi.org/10.1101/gr.216150.116>
- GABRIÉLS J., BECKERS M. C., DING H., DE VRIESE A., PLAISANCE S., VAN DER MAAREL S. M., PADBERG G. W., FRANTSR. R., HEWITT J. E., COLLEND, BELAYEW A. (1999). Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. *Gene* 236: 25-32. [https://doi.org/10.1016/S0378-1119\(99\)00267-X](https://doi.org/10.1016/S0378-1119(99)00267-X)
- GAINETDINOV I., SKVORTSOVA Y., KONDRATIEVA S., FUNIKOV S., AZHIKINA T. (2017). Two modes of targeting transposable elements by piRNA pathway in human testis. *RNA* 23: 1614-1625. <https://doi.org/10.1261/rna.060939.117>
- GAO L., WU K., LIU Z., YAO X., YUAN S., TAO W., YI L., YU G., HOU Z., FAN D., TIAN Y., LIU J., CHEN Z. J., LIU J. (2018). Chromatin Accessibility Landscape in Human Early Embryos and Its Association with Evolution. *Cell* 173: 248-259. <https://doi.org/10.1016/j.cell.2018.02.028>
- GAWRYSKI L., JOUHILAHTI E. M., YOSHIHARA M., FEI L., WELTNER J., AIRENNE T. T., TROKOVIC R., BHAGAT S., TERVANIEMI M. H., MURAKAWA Y., SALOKAS K., LIU X. *et al.* (2023). Comprehensive characterization of the embryonic factor LEUTX. *iScience* 26: 106172. <https://doi.org/10.1016/j.isci.2023.106172>
- GENG L. N., YAO Z., SNIDER L., FONG A. P., CECH J. N., YOUNG J. M., VAN DER MAAREL S. M., RUZZO W. L., GENTLEMAN R. C., TAWIL R., TAPSCOTT S. J. (2012). DUX4 Activates Germline Genes, Retroelements, and Immune Mediators: Implications for Facioscapulohumeral Dystrophy. *Developmental Cell* 22: 38-51. <https://doi.org/10.1016/j.devcel.2011.11.013>
- GÖKE J., LU X., CHAN Y. S., NG H. H., LY L. H., SACHS F., SZCZERBINSKA I. (2015). Dynamic Transcription of Distinct Classes of Endogenous Retroviral Elements Marks Specific Populations of Early Human Embryonic Cells. *Cell Stem Cell* 16: 135-141. <https://doi.org/10.1016/j.stem.2015.01.005>
- GROW E. J., FLYNN R. A., CHAVEZ S. L., BAYLESS N. L., WOSSIDLO M., WESCHE D. J., MARTIN L., WARE C. B., BLISH C. A., CHANG H. Y., REIJO PERA R. A., WYSOCKA J. (2015). Intrinsic retroviral reactivation in human preimplantation embryos and pluripotent cells. *Nature* 522: 221-225. <https://doi.org/10.1038/nature14308>
- GROW E. J., WEAVER B. D., SMITH C. M., GUO J., STEIN P., SHADLE S. C., HENDRICKSON P. G., JOHNSON N. E., BUTTERFIELD R. J., MENAFRA R., KLOET S. L., VAN DER MAAREL S. M. *et al.* (2021). p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models. *Nature Genetics* 53: 1207-1220. <https://doi.org/10.1038/s41588-021-00893-0>
- HAMM D. C., PAATELA E. M., BENNETT S. R., WONG C. J., CAMPBELL A. E., WLADYKA C. L., SMITH A. A., JAGANNATHAN S., HSIEH A. C., TAPSCOTT S. J. (2023). The transcription factor DUX4 orchestrates translational reprogramming by broadly suppressing translation efficiency and promoting expression of DUX4-induced mRNAs. *PLOS Biology* 21: e3002317. <https://doi.org/10.1371/journal.pbio.3002317>
- HASHIMOTO K., JOUHILAHTI E. M., TÖHÖNEN V., CARNINCIP, KERE J., KATAYAMA S. (2021). Embryonic LTR retrotransposons supply promoter modules to somatic tissues. *Genome Research* 31: 1983-1993. <https://doi.org/10.1101/gr.275354.121>
- HENDRICKSON P. G., DORÁIS J. A., GROW E. J., WHIDDON J. L., LIM J. W., WIKE C. L., WEAVER B. D., PFLUEGER C., EMERY B. R., WILCOX A. L., NIX D. A., PETERSON C. M. *et al.* (2017). Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL/HERVL retrotransposons. *Nature Genetics* 49: 925-934. <https://doi.org/10.1038/ng.3844>
- HEWITT J. E. (2015). Loss of epigenetic silencing of the DUX4 transcription factor gene in facioscapulohumeral muscular dystrophy. *Human Molecular Genetics* 24: R17-R23. <https://doi.org/10.1093/hmg/ddv237>
- JAGANNATHAN S., OGATA Y., GAFKEN P. R., TAPSCOTT S. J., BRADLEY R. K. (2019). Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy. *eLife* 8: e41740. <https://doi.org/10.7554/eLife.41740>
- JAGANNATHAN S., SHADLE S. C., RESNICK R., SNIDER L., TAWIL R. N., VAN DER MAAREL S. M., BRADLEY R. K., TAPSCOTT S. J. (2016). Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells. *Human Molecular Genetics* 25: 4419-4431. <https://doi.org/10.1093/hmg/ddw271>

- JANSSEN A., COLMENARESS. U., KARPEN G. H. (2018). Heterochromatin: Guardian of the Genome. *Annual Review of Cell and Developmental Biology* 34: 265-288. <https://doi.org/10.1146/annurev-cellbio-100617-062653>
- KOWALJOW V., MARCOWYCZ A., ANSSEAU E., CONDE C. B., SAUVAGE S., MATÉOTTI C., ARIAS C., CORONA E. D., NUÑEZ N. G., LEO O., WATTIEZ R., FIGLEWICZ D., LAOUDJ-CHENIVESSE D. *et al.* (2007). The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. *Neuromuscular Disorders* 17: 611-623. <https://doi.org/10.1016/j.nmd.2007.04.002>
- KRESOJA-RAKIC J., SANTORO R. (2019). Nucleolus and rRNA Gene Chromatin in Early Embryo Development. *Trends in Genetics* 35: 868-879. <https://doi.org/10.1016/j.tig.2019.06.005>
- LEE J. K., BOSNAKOVSKI D., TOSO E. A., DINH T., BANERJEE S., BOHL T. E., SHI K., ORELLANA K., KYBA M., AIHARA H. (2018). Crystal Structure of the Double Homeodomain of DUX4 in Complex with DNA. *Cell Reports* 25: 2955-2962.e3. <https://doi.org/10.1016/j.celrep.2018.11.060>
- LEE K.H., KIM D.Y., KIM W. (2021). Regulation of Gene Expression by Telomere Position Effect. *International Journal of Molecular Sciences* 22: 12807. <https://doi.org/10.3390/ijms222312807>
- LEIDENROTH A., CLAPP J., MITCHELL L. M., CONEY WORTH D., DEARDEN F. L., IANNUZZI L., HEWITT J. E. (2012). Evolution of DUX gene macrosatellites in placental mammals. *Chromosoma* 121: 489-497. <https://doi.org/10.1007/s00412-012-0380-y>
- LEIDENROTH A., HEWITT J. E. (2010). A family history of DUX4: phylogenetic analysis of DUXA, B, C and Duxbl reveals the ancestral DUX gene. *BMC Evolutionary Biology* 10: 364. <https://doi.org/10.1186/1471-2148-10-364>
- LEMMERS R. J. L. F., VAN DER VLIET P. J., KLOOSTER R., SACCONI S., CAMAÑO P., DAUWERSE J. G., SNIDER L., STRAASHEIJM K. R., JAN VAN OMMEN G., PADBERG G. W., MILLER D. G., TAPSCOTT S. J., TAWIL R., FRANTS R. R., VAN DER MAAREL S. M. (2010). A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy. *Science* 329: 1650-1653. <https://doi.org/10.1126/science.1189044>
- LIANG C.Y., WANG L.J., CHEN C.P., CHEN L.F., CHEN Y.H., CHEN H. (2010). GCM1 Regulation of the Expression of Syncytin 2 and Its Cognate Receptor MFS2A in Human Placenta 1. *Biology of Reproduction* 83: 387-395. <https://doi.org/10.1095/biolreprod.110.083915>
- LIU L., LENG L., LIU C., LU C., YUAN Y., WU L., GONG F., ZHANG S., WEI X., WANG M., ZHAO L., HU L., WANG J., YANG H., ZHU S., CHEN F., LU G., SHANG Z., LIN G. (2019). An integrated chromatin accessibility and transcriptome landscape of human pre-implantation embryos. *Nature Communications* 10: 364. <https://doi.org/10.1038/s41467-018-08244-0>
- LIU Y., LU X., YE M., WANG L., TANG R., YANG Z., TURATHUM B., LIU C., XUE Y., WU M., YANG Y., GAO E. *et al.* (2022). Efficient silencing of the multicopy DUX4 gene by ABE-mediated start codon mutation in human embryos. *Journal of Genetics and Genomics* 49: 982-985. <https://doi.org/10.1016/j.jgg.2022.02.010>
- MACAULAYE C., WEEKS R. J., ANDREWSS., MORISON I. M. (2011). Hypomethylation of functional retrotransposon-derived genes in the human placenta. *Mammalian Genome* 22: 722-735. <https://doi.org/10.1007/s00335-011-9355-1>
- MADISSOON E., JOUHILAHTI E.M., VESTERLUND L., TÖHÖNEN V., KRJUTŠKOV K., PETROPOULOS S., EINARSDOTTIR E., LINNARSSON S., LANNER F., MÅNSSON R., HOVATTA O., BÜRGLIN T. R., KATAYAMA S., KERE J. (2016). Characterization and target genes of nine human PRD-like homeobox domain genes expressed exclusively in early embryos. *Scientific Reports* 6: 28995. <https://doi.org/10.1038/srep28995>
- MAZID M. A., WARD C., LUO Z., LIU C., LI Y., LAI Y., WU L., LI J., JIA W., JIANG Y., LIU H., FU L. *et al.* (2022). Rolling back human pluripotent stem cells to an eight-cell embryo-like stage. *Nature* 605: 315-324. <https://doi.org/10.1038/s41586-022-04625-0>
- MITSUHASHI H., ISHIMARU S., HOMMA S., YU B., HONMA Y., BEERMANN M. L., MILLER J. B. (2018). Functional domains of the FSHD-associated DUX4 protein. *Biology Open* 7: bio033977. <https://doi.org/10.1242/bio.033977>
- MOYA-JÓDAR M., ULLATE-AGOTE A., BARLABÉ P., RODRÍGUEZ-MADOZ J. R., ABIZANDA G., BARREDA C., CARVAJAL-VERGARA X., VILAS-ZORNOZA A., ROMERO J. P., GARATE L., AGIRRE X., COPPIELLO G. *et al.* (2023). Revealing cell populations catching the early stages of human embryo development in naive pluripotent stem cell cultures. *Stem Cell Reports* 18: 64-80. <https://doi.org/10.1016/j.stemcr.2022.11.015>
- PALOVIIITA P., VUORISTO S. (2022). The non-coding genome in early human development – Recent advancements. *Seminars in Cell & Developmental Biology* 131: 4-13. <https://doi.org/10.1016/j.semcd.2022.02.010>
- PETROPOULOS S., PANULA S. P., SCHELL J. P., LANNER F. (2016). Single-cell RNA sequencing: revealing human pre-implantation development, pluripotency and germline development. *Journal of Internal Medicine* 280: 252-264. <https://doi.org/10.1111/joim.12493>
- PONTIS J., PLANET E., OFFNER S., TURELLI P., DUC J., COUDRAY A., THEUNISSEN T. W., JAENISCH R., TRONO D. (2019). Hominoid-Specific Transposable Elements and KZFPs Facilitate Human Embryonic Genome Activation and Control Transcription in Naive Human ESCs. *Cell Stem Cell* 24: 724-735.e5. <https://doi.org/10.1016/j.stem.2019.03.012>
- RAISNER R., KHARBANDA S., JIN L., JENG E., CHAN E., MERCHANT M., HAVERTY P. M., BAINER R., CHEUNG T., ARNOTT D., FLYNN E. M., ROMERO F. A. *et al.* (2018). Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. *Cell Reports* 24: 1722-1729. <https://doi.org/10.1016/j.celrep.2018.07.041>
- RESNICK R., WONG C.J., HAMM D. C., BENNETT S. R., SKENE P. J., HAKE S. B., HENIKOFF S., VAN DER MAAREL S. M., TAPSCOTT S. J. (2019). DUX4-Induced Histone Variants H3.X and H3.Y Mark DUX4 Target Genes for Expression. *Cell Reports* 29: 1812-1820.e5. <https://doi.org/10.1016/j.celrep.2019.10.025>
- RICKARD A. M., PETEK L. M., MILLER D. G. (2015). Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways. *Human Molecular Genetics* 24: 5901-5914. <https://doi.org/10.1093/hmg/ddv315>
- SACCONI S., BRIAND-SULEAU A., GROS M., BAUDOIN C., LEMMERS R. J.L.F., RONDEAU S., LAGHA N., NIGUMANN P., CAMBIERI C., PUMA A., CHAPON F., STOJKOVIC T. *et al.* (2019). FSHD1 and FSHD2 form a disease continuum. *Neurology* 92: e2273–e2285. <https://doi.org/10.1212/WNL.0000000000007456>
- SCHULZ K. N., HARRISON M. M. (2019). Mechanisms regulating zygotic genome activation. *Nature Reviews Genetics* 20: 221-234. <https://doi.org/10.1038/s41576-018-0087-x>
- SHADLE S. C., ZHONG J. W., CAMPBELL A. E., CONERLY M. L., JAGANNATHAN S., WONG C.J., MORELLO T. D., VAN DER MAAREL S. M., TAPSCOTT S. J. (2017). DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy. *PLoS Genetics* 13: e1006658. <https://doi.org/10.1371/journal.pgen.1006658>
- SMITH A. A., NIP Y., BENNETT S. R., HAMM D. C., LEMMERS R. J.L.F., VAN DER VLIET P. J., SETTY M., VAN DER MAAREL S. M., TAPSCOTT S. J. (2023). DUX4 expression in cancer induces a metastable early embryonic totipotent program. *Cell Reports* 42: 113114. <https://doi.org/10.1016/j.celrep.2023.113114>
- SNIDER L., GENG L. N., LEMMERS R. J. L. F., KYBA M., WARE C. B., NELSON A. M., TAWIL R., FILIPPOVA G. N., VAN DER MAAREL S. M., TAPSCOTT S. J., MILLER D. G. (2010). Facioscapulohumeral Dystrophy: Incomplete Suppression of a Retrotransposed Gene. *PLoS Genetics* 6: e1001181. <https://doi.org/10.1371/journal.pgen.1001181>
- STADLER G., RAHIMOV F., KING O. D., CHEN J. C. J., ROBIN J. D., WAGNER K. R., SHAY J. W., EMERSON C. P., WRIGHT W. E. (2013). Telomere position effect regulates DUX4 in human facioscapulohumeral muscular dystrophy. *Nature Structural & Molecular Biology* 20: 671-678. <https://doi.org/10.1038/nsmb.2571>
- TAUBENSCHMID-STOWERS J., ROSTOVSKAYA M., SANTOS F., LJUNG S., ARGELAGUET R., KRUEGER F., NICHOLS J., REIK W. (2022). 8C-like cells capture the human zygotic genome activation program in vitro. *Cell Stem Cell* 29: 449-459.e6. <https://doi.org/10.1016/j.stem.2022.01.014>
- TESAŘEK J., KOPEČNÝ V., PLACHOT M., MANDELBAUM J. (1988). Early morphological signs of embryonic genome expression in human preimplantation development as revealed by quantitative electron microscopy. *Developmental Biology* 128: 15-20. [https://doi.org/10.1016/0012-1606\(88\)90261-8](https://doi.org/10.1016/0012-1606(88)90261-8)
- TESARIK J., KOPEČNÝ V., PLACHOT M., MANDELBAUM J. (1986). Activation of nucleolar and extranucleolar RNA synthesis and changes in the ribosomal content of human embryos developing in vitro. *Reproduction* 78: 463-470. <https://doi.org/10.1530/jrf.0.0780463>
- TÖHÖNEN V., KATAYAMA S., VESTERLUND L., JOUHILAHTI E.M., SHEIKHI M., MADISSOON E., FILIPPINI-CATTANEO G., JACONI M., JOHNSSON A., BÜRGLIN T. R., LINNARSSON S., HOVATTA O., KERE J. (2015). Novel PRD-like homeodomain transcription factors and retrotransposon elements in early human development. *Nature Communications* 6: 8207. <https://doi.org/10.1038/ncomms9207>
- TÖHÖNEN V., KATAYAMA S., VESTERLUND L., SHEIKHI M., ANTONSSON L., FILIPPINI-CATTANEO G., JACONI M., JOHNSSON A., LINNARSSON S., HOVATTA O., KERE J. (2017). Transcription activation of early human development suggests DUX4 as an embryonic regulator. *bioRxiv Preprint*: 123208. <https://doi.org/10.1101/123208>

- VAN DE WERKEN C., VAN DER HEIJDEN G. W., ELEVELD C., TEEUWSEN M., ALBERT M., BAARENS W. M., LAVEN J. S. E., PETERS A. H. F. M., BAART E. B. (2014). Paternal heterochromatin formation in human embryos is H3K9/HP1 directed and primed by sperm-derived histone modifications. *Nature Communications* 5: 5868. <https://doi.org/10.1038/ncomms6868>
- VASSENA R., BOUÉ S., GONZÁLEZ-ROCA E., ARAN B., AUER H., VEIGA A., BELMONTE J. C. I. (2011). Waves of early transcriptional activation and pluripotency program initiation during human preimplantation development. *Development* 138: 3699-3709. <https://doi.org/10.1242/dev.064741>
- VASTENHOUW N. L., CAO W. X., LIPSHITZ H. D. (2019). The maternal-to-zygotic transition revisited. *Development* 146: dev161471. <https://doi.org/10.1242/dev.161471>
- VEGA-SENDINO M., LÜTTMANN F. F., OLBRICH T., CHEN Y., KUENNE C., STEIN P., TILLO D., CAREY G. I., ZHONG J., SAVY V., RADONOVA L., LU T. *et al.* (2024). The homeobox transcription factor DUXBL controls exit from totipotency. *Nature genetics* 56: 697-709. <https://doi.org/10.1038/s41588-024-01692-z>
- VUORISTO S., BHAGAT S., HYDÉN-GRANSKOG C., YOSHIHARA M., GAWRIYSKI L., JOUHILAHTI E. M., RANGA V., TAMIRAT M., HUHTALA M., KIRJANOV I., NYKÄNEN S., KRJUTŠKOV K. *et al.* (2022). DUX4 is a multifunctional factor priming human embryonic genome activation. *iScience* 25: 104137. <https://doi.org/10.1016/j.isci.2022.104137>
- WALLACE L. M., GARWICK S. E., MEI W., BELAYEW A., COPPEE F., LADNER K. J., GUTTRIDGE D., YANG J., HARPER S. Q. (2011). DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. *Annals of Neurology* 69: 540-552. <https://doi.org/10.1002/ana.22275>
- WHIDDON J. L., LANGFORD A. T., WONG C. J., ZHONG J. W., TAPSCOTT S. J. (2017). Conservation and innovation in the DUX4-family gene network. *Nature Genetics* 49: 935-940. <https://doi.org/10.1038/ng.3846>
- WU J., XU J., LIU B., YAO G., WANG P., LIN Z., HUANG B., WANG X., LI T., SHI S., ZHANG N., DUAN F. *et al.* (2018). Chromatin analysis in human early development reveals epigenetic transition during ZGA. *Nature* 557: 256-260. <https://doi.org/10.1038/s41586-018-0080-8>
- XIA W., XU J., YU G., YAO G., XU K., MA X., ZHANG N., LIU B., LI T., LIN Z., CHEN X., LI L., WANG Q. *et al.* (2019). Resetting histone modifications during human parental-to-zygotic transition. *Science* 365: 353-360. <https://doi.org/10.1126/science.aaw5118>
- XIE S. Q., LEEKE B. J., WHILDING C., WAGNER R. T., GARCIA-LLAGOSTERA F., LOW Y. X., CHAMMAS P., CHEUNG N. T. F., DORMANN D., MCMANUS M. T., PERCHARDE M. (2022). Nucleolar-based Dux repression is essential for embryonic two-cell stage exit. *Genes & Development* 36: 331-347. <https://doi.org/10.1101/gad.349172.121>
- XU R., LI S., WU Q., LI C., JIANG M., GUO L., CHEN M., YANG L., DONG X., WANG H., WANG C., LIU X., OU X., GAO S. (2022). Stage-specific H3K9me3 occupancy ensures retrotransposon silencing in human pre-implantation embryos. *Cell Stem Cell* 29: 1051-1066.e8. <https://doi.org/10.1016/j.stem.2022.06.001>
- XUE Z., HUANG K., CAI C., CAI L., JIANG C., FENG Y., LIU Z., ZENG Q., CHENG L., SUN Y. E., LIU J., HORVATH S., FAN G. (2013). Genetic programs in human and mouse early embryos revealed by single-cell RNA sequencing. *Nature* 500: 593-597. <https://doi.org/10.1038/nature12364>
- YAN L., YANG M., GUO H., YANG L., WU J., LI R., LIU P., LIAN Y., ZHENG X., YAN J., HUANG J., LI M. *et al.* (2013). Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells. *Nature Structural & Molecular Biology* 20: 1131-1139. <https://doi.org/10.1038/nsmb.2660>
- YOSHIHARA M., KIRJANOV I., NYKÄNEN S., SOKKA J., WELTNER J., LUNDIN K., GAWRIYSKI L., JOUHILAHTI E. M., VARJOSALO M., TERVANIEMI M. H., OTONKOSKI T., TROKOVIC R. *et al.* (2022). Transient DUX4 expression in human embryonic stem cells induces blastomere-like expression program that is marked by SLC34A2. *Stem Cell Reports* 17: 1743-1756. <https://doi.org/10.1016/j.stemcr.2022.06.002>
- YOUNG J. M., WHIDDON J. L., YAO Z., KASINATHAN B., SNIDER L., GENG L. N., BALOG J., TAWIL R., VAN DER MAAREL S. M., TAPSCOTT S. J. (2013). DUX4 Binding to Retroelements Creates Promoters That Are Active in FSHD Muscle and Testis. *PLoS Genetics* 9: e1003947. <https://doi.org/10.1371/journal.pgen.1003947>
- YU H., CHEN M., HU Y., OU S., YU X., LIANG S., LI N., YANG M., KONG X., SUN C., JIA S., ZHANG Q. *et al.* (2022). Dynamic reprogramming of H3K9me3 at hominoid-specific retrotransposons during human preimplantation development. *Cell Stem Cell* 29: 1031-1050.e12. <https://doi.org/10.1016/j.stem.2022.06.006>
- YU H., SUN Z., TAN T., PAN H., ZHAO J., ZHANG L., CHEN J., LEI A., ZHU Y., CHEN L., XU Y., LIU Y. *et al.* (2021). rRNA biogenesis regulates mouse 2C-like state by 3D structure reorganization of peri-nucleolar heterochromatin. *Nature Communications* 12: 6365. <https://doi.org/10.1038/s41467-021-26576-2>
- YU X., LIANG S., CHEN M., YU H., LI R., QU Y., KONG X., GUO R., ZHENG R., IZSVÁK Z., SUN C., YANG M., WANG J. (2022). Recapitulating early human development with 8C-like cells. *Cell Reports* 39: 110994. <https://doi.org/10.1016/j.celrep.2022.110994>
- ZHANG X., ZHANG C., ZHOU D., ZHANG T., CHEN X., REN J., HE C., MENG F., ZHOU Q., YANG Q., DAI C., LIN G. *et al.* (2023). Telomeres cooperate in zygotic genome activation by affecting DUX4/Dux transcription. *iScience* 26: 106158. <https://doi.org/10.1016/j.isci.2023.106158>
- ZOU Z., ZHANG C., WANG Q., HOU Z., XIONG Z., KONG F., WANG Q., SONG J., LIU B., LIU B., WANG L., LAI F. *et al.* (2022). Translatome and transcriptome co-profiling reveals a role of TPRXs in human zygotic genome activation. *Science* 378: abo7923. <https://doi.org/10.1126/science.abo7923>